







A.**B.****C.****FIG. 1**

A.**B.****C.****FIG. 2**






FIG. 3

A.



B.



C.






FIG. 4

A.



B.



C.






FIG. 5

A.



B.



C.





FIG. 6

A.



B.





FIG. 7

A.



B.





FIG. 8

A.



B.







FIG. 9

A.**B.****FIG. 10**

A.



B.






FIG. 11

**A. anti-Flt3L Candidate clones
RS4;11(96pM huFLT3L)**



	IC50 (pM)
FLT3-Fc	213
R&D mAb608	76.3
5D9 Parental	318,100
C06	293


**B. anti-Flt3L Antibodies
RS4;11(96pM)**



	IC50 (pM)
FLT3-Fc	198
R&D mAb608	68
5D9 Parental	248,300
C06	334
SC4017	72
AM40	83

FIG. 12

A.



B.

Neutralization of endogenous Cell-bound FLT3L




FIG. 13





FIG. 14

A.



B.




FIG. 15




FIG. 16




FIG. 17





FIG. 18

A.

17 weeks Proteinuria



B.

EOS Combined Nephritis Score









FIG. 19

A.**B.****C.****FIG. 20**

A.**SG Pathology score- Therapeutic****B.****SG Pathology score- Prophylactic****FIG. 21**




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27